You are about to leave the website of the Global Health Institute of Merck KGaA, Darmstadt, Germany

Integrated Solutions

Global Health Institute, delivering integrated solutions to reach impact

The Institute aims at supporting global control agendas to reach elimination of specific infectious diseases. A defined strategic intent is developed for each disease that aligns and integrates the development of treatments addressing high unmet medical needs together with new diagnostic tools to detect infections and of new products to improve prevention against transmission of infectious pathogens and of programs strengthening endemic countries health systems.

image-1

Treatment

Addressing disease-specific key unmet medical needs for children and mothers/pregnant women by discovering and developing the next generation of drugs and medical devices in:

Malaria

  • To address the fight against anti-malaria drug resistance
  • To develop new treatments to block transmission
  • To identify new compounds preventing liver infection
  • To advance innovative approaches to prevent seasonal or episodic infections
  • To conduct development for pediatric populations and pregnant women in endemic countries together with local partners
  • To apply stringent regulatory path (FDA, EMA) to registration including WHO prequalification

Schistosomiasis

  • To develop a pediatric formulation of Praziquantel for children below 6 years of age. The Praziquantel donation through Mass Drug Administration (MDA) campaigns targets school-aged children but today there is a major gap in treating pre-school-aged children, a population also suffering from Schistosomiasis infection.
  • To develop new treatments to block juvenile formation of schistosomes
  • To identify new compounds to address the potential emergence of resistance
  • To conduct development for vulnerable populations in endemic countries together with local partners
  • To apply stringent regulatory path (FDA, EMA) to registration including WHO prequalification

Diagnostics & Technologies

Focusing on developing and producing affordable, highly sensitive and specific diagnostic tools to address key disease-specific needs to improve patient identification, treatment efficacy and support control and elimination in:

Malaria

  • To identify P. falciparum and P. vivax clinically-silent patients to block continued transmission
  • To quantify parasitemia levels to instruct treatment approach
  • To develop multi-detection platforms to address co-infections in endemic populations
  • To conduct development in endemic countries together with local partners
  • To apply stringent regulatory path (FDA, EMA) to registration including WHO prequalification

Schistosomiasis

  • To identify new biomarkers of Schistosoma hematobium and Schistosoma mansoni infections to develop more sensitive diagnostics in comparison to currently available standard methods
  • To develop methods to improve detection sensitivity in populations presenting mid-to-low egg burden to better assess progress of morbidity control and interruption of transmission
  • To conduct development in endemic countries together with local partners
  • To apply stringent regulatory path (FDA, EMA) to registration including WHO prequalification

Bacterial infections

  • To develop laboratory technologies to speed up accurate detection of infectious pathogens
  • To develop multi-detection platforms to address co-infections in endemic populations to reduce the unnecessary use of antimicrobials
  • To conduct development in endemic countries together with local partners
  • To apply stringent regulatory path (FDA, EMA) to registration including WHO prequalification

Vector Control

Development of products & technologies to prevent disease-specific infections in:

Malaria

  • To advance the development of insect repellents as personal protection against anopheles bites to complement bed nets approaches

Schistosomiasis

  • To evaluate the potential of bringing to life a new generation of snails protected against infection in order to stop schistosomiasis transmission
  • To elaborate activities with the WASH (water, sanitation and health) sector to support behavioral change interventions

Health System Strengthening

Building capacity, educational programs and developing technologies to provide impactful knowledge to policy makers and to strengthen local healthcare systems in:

Malaria

  • To supporting Ph.D programs to build knowledge locally while generating research for better understanding on biology of malaria in endemic countries
  • To support post-doctoral fellows to grow research capacities locally

Schistosomiasis

  • To construct a pediatric ward (Ivory Coast) by the Pediatric Praziquantel Consortium to host future clinical trials
  • To construct a gynecological ward (Cameroon) in collaboration with CIRES to generate epidemiological data on Female Genital Schistosomiasis and its impact on women’s health
  • To support young researchers to grow research capacity locally

Antimicrobial Resistance

  • To support local medical master programs on AMR, infection control programs and stewardship in Makerere University (Uganda) to develop guidance and policies with the Ministry of Health

Other

  • To share Pharma knowledge to build local clinical capacity through hosting EDCTP fellows